Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1

Interventions

pembrolizumab 29Carboplatin 15Cisplatin 13Nivolumab 12atezolizumab 10Radiotherapy 10Paclitaxel 10Ipilimumab 10venetoclax 9Pemetrexed 9Docetaxel 9durvalumab 8Gemcitabine 8fludarabine 7Specimen Handling 7Cyclophosphamide 7Bevacizumab 7tislelizumab 6fludarabine phosphate 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6enzalutamide 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × ponatinib × 90 days × Clear all
NCT05268003 2026-04-27

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
4 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡